KIT mutations are found at low frequencies (10 %) in melanomas arising from mucosal or acral lentiginous surfaces [27]
Understanding the whole patient prior to receiving transplant and cellular therapy: Real-world data on patients financial toxicity prior to receiving treatment Miranda Kapfhammer 1 , Rachel Cusatis 1 , Deborah Mattila 2 , Sarah Smith 2 1 Medical College of Wisconsin, Milwaukee, USA, 2 National Marrow Donor Program (NMDP), Minneapolis, USA Aims Cellular therapy (CT) recipients are at high risk for financial toxicity (FT) given the frequent need for temporary re-location, loss of income for patients and caregivers in addition to the expected medical expenses of cancer care
Adrian stocked up on three months of compounded tirzepatide, but he worried that the FDA would shut down his provider before he could afford to stockpile more medication
Orforglipron, an oral GLP-1, can deliver similar weight loss benefits to tirzepatide, though its slightly less effective